University of Texas Texas AM Investment Management Co. Has $5.79 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• The University of Texas Texas AM Investment Management Co. reduced its stake in Eli Lilly and Company by 16.2%, owning 7,007 shares after selling 1,350 shares.
• Several institutional investors increased their holdings in Eli Lilly, with GAMMA Investing LLC lifting its stake by an astonishing 103,831.6%, now owning nearly 14.87 million shares valued at over $12 billion.
• Analysts have mixed views on the stock, with a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

University of Texas Texas AM Investment Management Co. reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,007 shares of the company's stock after selling 1,350 shares during the period. Eli Lilly and Company makes up about 1.0% of University of Texas Texas AM Investment Management Co.'s investment portfolio, making the stock its 19th biggest position. University of Texas Texas AM Investment Management Co.'s holdings in Eli Lilly and Company were worth $5,787,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $43,000. Finally, O Brien Wealth Partners LLC raised its stake in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $4.05 on Thursday, hitting $756.03. The company had a trading volume of 2,399,454 shares, compared to its average volume of 3,776,412. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market cap of $716.52 billion, a price-to-earnings ratio of 61.52, a P/E/G ratio of 1.08 and a beta of 0.40. The stock has a 50 day moving average price of $774.07 and a 200 day moving average price of $800.13. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company posted $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Guggenheim raised their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.